KRAS and neoplasm: Because PTEN deficiency and mutationally-activated KRAS can synergistically co-regulate tumor morphology in transgenic mice [51], we studied a larger series of 92 KRAS genotyped CRCs (cohort ii) and found CM on low power microscopy in 43% CRCs.